Tandem Diabetes Care Announces No-Cost Software Updates for t:slim X2 Insulin Pump Customers in the United States
August 01 2019 - 4:02PM
Business Wire
Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin
delivery and diabetes technology company, today announced it is
offering no-cost feature updates for t:slim X2 insulin pump
customers in the United States through the end of 2020.
- All software updates approved by the U.S. Food and Drug
Administration (FDA) through the end of 2020 will be offered for no
cost
- Customers who purchase a pump prior to December 31, 20201,
including current customers, are eligible for software updates
while in-warranty
- Software updates will be offered through the Tandem Device
Updater
“Our ability to provide our customers with remote feature
updates exemplifies our Company’s mission to improve the lives of
people with diabetes through relentless innovation and
revolutionary customer experience,” said John Sheridan, president
and CEO of Tandem Diabetes Care. “We see great value in our
software updates, both big and small. We believe easy access to the
latest t:slim X2 features as they are approved can help improve the
lives of our customers, encourage more people to adopt pump
therapy, and further reinforce the benefit of our technology with
insurance providers.”
Tandem is the only company offering a tool for remote software
updates for its insulin pumps as new features are approved by the
FDA. The Company previously demonstrated its market-differentiating
Tandem Device Updater in 2017 by successfully providing CGM
integration to thousands of t:slim X2 customers for no cost
following FDA approval of the t:slim X2 insulin pump with Dexcom G5
Mobile CGM integration, and again in 2018 following FDA approval of
the t:slim X2 insulin pump with Basal-IQ technology.
About the t:slim X2 Insulin Pump with Basal-IQ
Technology
The simple-to-use t:slim X2 insulin pump with Basal-IQ
predictive low glucose suspend technology uses glucose values from
an integrated Dexcom G6 continuous glucose monitor to predict and
help prevent lows. The t:slim X2 pump includes advanced features
like a large color touchscreen, rechargeable battery, Bluetooth®
wireless technology, USB connectivity and watertight construction
(IPX7)2. It is capable of remote software updates using a personal
computer, offering the potential for users to access new features
as they meet necessary regulatory requirements. The t:slim X2 Pump
is up to 38 percent smaller than other insulin pumps and holds up
to 300 units of insulin.3
For additional product and safety information,
visit www.tandemdiabetes.com/tslimX2info or call (877) 801-6901,
Monday – Friday between 6am and 5pm Pacific Time
Free t:slim X2 Pump Demo on Your Mobile Device
Download Tandem’s free t:simulator™ App to experience the
touchscreen interface of the t:slim X2 pump with Basal-IQ
technology directly on your mobile device. For more information and
to download the app, visit
http://www.tandemdiabetes.com/tsimulator.
About Tandem Diabetes Care, Inc.
Tandem Diabetes Care, Inc. (www.tandemdiabetes.com) is a medical
device company dedicated to improving the lives of people with
diabetes through relentless innovation and revolutionary customer
experience. The Company takes an innovative, user-centric approach
to the design, development and commercialization of products for
people with diabetes who use insulin. Tandem’s flagship product,
the t:slim X2 insulin pump, is capable of remote software updates
using a personal computer and features integrated continuous
glucose monitoring. Tandem is based in San Diego, California.
Tandem Diabetes Care and Basal-IQ are registered trademarks, and
t:slim X2 and t:simulator are trademarks of Tandem Diabetes Care,
Inc. Dexcom, Dexcom G5 and Dexcom G6 are registered trademarks of
Dexcom, Inc. The Bluetooth word mark and logos are registered
trademarks owned by Bluetooth SIG, Inc. and any use of such marks
by Tandem Diabetes Care, Inc. is under license. All other
trademarks are the property of their respective owners.
Forward Looking Statement
This press release contains “forward-looking statements” within
the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, that concern matters that involve risks and uncertainties
that could cause actual results to differ materially from those
anticipated or projected in the forward-looking statements. These
forward-looking statements include statements regarding the
Company’s plans to make new t:slim X2 pump software updates
approved by the FDA through 2020 available to in-warranty t:slim X2
pump users at no cost and the Company’s belief that easier access
to new pump features can help improve the lives of customers,
encourage more people to adopt pump therapy, and further reinforce
the benefit of the Company’s technology with insurance providers.
The Company's actual results may differ materially from those
indicated in these forward-looking statements due to numerous risks
and uncertainties, including the Company’s ability to complete the
development and obtain required FDA approvals to offer future
software updates using the Tandem Device Updater, the potential
that competitive products or other technological developments and
breakthroughs for the monitoring, treatment or prevention of
diabetes may render the Company’s products obsolete or less
desirable or that the Company’s products may not provide the
expected benefits to users or insurance providers. Other risks and
uncertainties are identified in the Company’s most recent Annual
Report on Form 10-K and Quarterly Report on Form 10-Q, and other
documents that the Company files with the Securities and Exchange
Commission. Investors are cautioned not to place undue reliance on
these forward-looking statements, which speak only as of the date
of this release. Tandem undertakes no obligation to update or
review any forward-looking statement in this press release because
of new information, future events or other factors.
1 Additional feature updates are not currently available for the
t:slim X2 pump with Basal-IQ technology and are subject to future
FDA approvals. A prescription and additional training may be
required to access certain future software updates. Offer only
available to customers who reside in the United States, who are in
warranty at the time they update their pump and who purchased a
t:slim X2 insulin pump on or before December 31, 2020. Tandem may
discontinue select software and features over time at its
discretion. This is a limited time offer and Tandem reserves the
right to discontinue this program at its discretion. 2 Tested to a
depth of 3 feet for 30 minutes 3 38 percent smaller than MiniMed
630G and 670G and at least 28 percent smaller than MiniMed 530G,
Animas Vibe and Omnipod System. Data on file, Tandem Diabetes
Care.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20190801005977/en/
Media: Steve Sabicer, 714-907-6264, ssabicer@thesabicergroup.com
Investors: Susan Morrison, 858-366-6900 x7005,
IR@tandemdiabetes.com
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tandem Diabetes Care (NASDAQ:TNDM)
Historical Stock Chart
From Apr 2023 to Apr 2024